NEW YORK (TheStreet) -- CHANGE IN RATINGS
Activision (ATVI) was upgraded at Bank of America/Merrill Lynch to buy from neutral. Twelve-month price target is $25. Company can post better near-term earnings growth, Bank of America/Merrill said.
Cabela's (CAB) was upgraded at William Blair to outperform from market perform. Company can accelerate growth in the coming quarters, William Blair said.
Dynegy (DYN) was initiated with a sell rating at TheStreet Ratings.
Electronic Arts (EA) was downgraded at Bank of America/Merrill Lynch to neutral from buy. Twelve-month price target is now $35. Company lacks near-term catalysts, BofA/Merrill said.
Express (EXPR) was downgraded at UBS to neutral from buy. Underwhelming guidance with questionable execution and brand relevancy, UBS said. Twelve-month price target is now $17.
MagnaChip (MX) was downgraded to hold at TheStreet Ratings.
PVH (PVH) was downgraded at Morgan Stanley to equal-weight. New analyst sees an increasingly promotional environment, Morgan Stanley said.
Stock Comments / EPS Changes
Adobe Systems (ADBE) price target, EPS estimates were increased at Jefferies. Driven by new user growth, Enterprise ARR ramp and lack of alternatives for CS users, Jefferies said. Twelve-month price target is $80. Buy rating.
Eros International (EROS) price target was raised at UBS. Driven by healthy top-line growth with solid performance of the film slate and greater contribution from the film catalog, UBS said. Twelve-month price target is $18. Buy rating.
Envision (EVHC) estimates, price target were increased at Cantor Fitzgerald. Estimates were raised through 2015. Company can grow both organically and through acquisitions, Cantor Fitzgerald said. Buy rating and new 12-month price target of $40.
Express (EXPR) estimates, price target were cut at Nomura. Twelve-month price target is now $20. Estimates also reduced, as management cut guidance, because of weak traffic trends, Nomura said. Buy rating.
Healthcare Services Group (HCSG) price target was raised at Jefferies. Continued margin improvement and 10%-15% top-line growth expected, Jefferies said. Dining infrastructure is also better utilized, Jefferies said. Twelve-month price target is $29. Hold rating.
Pfizer (PFE) estimates were reduced at MKM Partners. Estimates were cut through 2015. Celebrex is facing increased generic competition, MKM Partners said. Neutral rating and 12-month price target of $29.
Sigma-Aldrich (SIAL) price target was raised at UBS. Driven by targeting organic growth with greater market penetration and growing focus on translational work, UBS said. Twelve-month price target is $86. Sell rating.
Williams-Sonoma (WSM) price target, EPS estimates were raised at Jefferies. Driven by unit expansion of West Elm and early returns on market share grab overseas, Jefferies said. Twelve-month price target is $72. Buy rating.